Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 263

1.

Modification of existing patient-reported outcome measures: qualitative development of the MD Anderson Symptom Inventory for malignant pleural mesothelioma (MDASI-MPM).

Williams LA, Whisenant MS, Mendoza TR, Haq S, Keating KN, Cuffel B, Cleeland CS.

Qual Life Res. 2018 Dec;27(12):3229-3241. doi: 10.1007/s11136-018-1982-5. Epub 2018 Sep 5.

PMID:
30187393
2.

Concept domain validation and item generation for the Treatment-Induced Neuropathy Assessment Scale (TNAS).

Williams LA, Garcia-Gonzalez A, Mendoza TR, Haq S, Cleeland CS.

Support Care Cancer. 2018 Aug 10. doi: 10.1007/s00520-018-4391-y. [Epub ahead of print]

PMID:
30094731
3.

Removal and insertion of central venous catheters in cancer patients is associated with high symptom burden.

Raad S, Chaftari AM, Hachem RY, Shah P, Natividad E, Cleeland CS, Rosenblatt J.

Expert Rev Med Devices. 2018 Aug;15(8):591-596. doi: 10.1080/17434440.2018.1500892. Epub 2018 Aug 1.

PMID:
30067125
4.

Patient-reported lung symptoms as an early signal of impending radiation pneumonitis in patients with non-small cell lung cancer treated with chemoradiation: an observational study.

Yue J, Shi Q, Xu T, Jeter M, Chen TY, Komaki R, Gomez DR, Pan T, Cleeland CS, Liao Z, Wang XS.

Qual Life Res. 2018 Jun;27(6):1563-1570. doi: 10.1007/s11136-018-1834-3. Epub 2018 Mar 16.

PMID:
29549533
5.

Utility of a patient-reported outcome in measuring functional impairment during autologous stem cell transplant in patients with multiple myeloma.

Shah N, Shi Q, Giralt S, Williams L, Bashir Q, Qazilbash M, Champlin RE, Cleeland CS, Wang XS.

Qual Life Res. 2018 Apr;27(4):979-985. doi: 10.1007/s11136-017-1759-2. Epub 2017 Dec 19.

PMID:
29260444
6.

Correction to: Long-term patient reported outcomes following radiation therapy for oropharyngeal cancer: cross-sectional assessment of a prospective symptom survey in patients ≥65 years old.

MD Anderson Head and Neck Cancer Symptom Working Group, Eraj SA, Jomaa MK, Rock CD, Mohamed ASR, Smith BD, Smith JB, Browne T, Cooksey LC, Williams B, Temple B, Preston KE, Aymard JM, Gross ND, Weber RS, Hessel AC, Ferrarotto R, Phan J, Sturgis EM, Hanna EY, Frank SJ, Morrison WH, Goepfert RP, Lai SY, Rosenthal DI, Mendoza TR, Cleeland CS, Hutcheson KA, Fuller CD, Garden AS, Brandon Gunn G.

Radiat Oncol. 2017 Nov 23;12(1):186. doi: 10.1186/s13014-017-0921-x.

7.

The contribution of pain in determining the health status of cancer patients with bone metastases: A secondary analysis of data from three Phase III registration trials.

Mendoza TR, Dueck AC, Shi Q, Ma H, Zhang J, Qian Y, Cleeland CS.

Eur J Pain. 2018 Mar;22(3):565-571. doi: 10.1002/ejp.1139. Epub 2017 Oct 30.

PMID:
29082574
8.

Long-term patient reported outcomes following radiation therapy for oropharyngeal cancer: cross-sectional assessment of a prospective symptom survey in patients ≥65 years old.

MD Anderson Head and Neck Cancer Symptom Working Group, Eraj SA, Jomaa MK, Rock CD, Mohamed ASR, Smith BD, Smith JB, Browne T, Cooksey LC, Williams B, Temple B, Preston KE, Aymard JM, Gross ND, Weber RS, Hessel AC, Ferrarotto R, Phan J, Sturgis EM, Hanna EY, Frank SJ, Morrison WH, Goepfert RP, Lai SY, Rosenthal DI, Mendoza TR, Cleeland CS, Hutcheson KA, Fuller CD, Garden AS, Gunn GB.

Radiat Oncol. 2017 Sep 9;12(1):150. doi: 10.1186/s13014-017-0878-9. Erratum in: Radiat Oncol. 2017 Nov 23;12 (1):186.

9.

Evaluation of different recall periods for the US National Cancer Institute's PRO-CTCAE.

Mendoza TR, Dueck AC, Bennett AV, Mitchell SA, Reeve BB, Atkinson TM, Li Y, Castro KM, Denicoff A, Rogak LJ, Piekarz RL, Cleeland CS, Sloan JA, Schrag D, Basch E.

Clin Trials. 2017 Jun;14(3):255-263. doi: 10.1177/1740774517698645. Epub 2017 Mar 20.

10.

Validation of the Persian Version of the Brief Pain Inventory (BPI-P) in Chronic Pain Patients.

Majedi H, Dehghani SS, Soleyman-Jahi S, Emami Meibodi SA, Mireskandari SM, Hajiaghababaei M, Tafakhori A, Mendoza TR, Cleeland CS.

J Pain Symptom Manage. 2017 Jul;54(1):132-138.e2. doi: 10.1016/j.jpainsymman.2017.02.017. Epub 2017 May 4.

PMID:
28479416
11.

Phase II study of the c-MET inhibitor tivantinib (ARQ 197) in patients with relapsed or relapsed/refractory multiple myeloma.

Baljevic M, Zaman S, Baladandayuthapani V, Lin YH, de Partovi CM, Berkova Z, Amini B, Thomas SK, Shah JJ, Weber DM, Fu M, Cleeland CS, Wang XS, Stellrecht CM, Davis RE, Gandhi V, Orlowski RZ.

Ann Hematol. 2017 Jun;96(6):977-985. doi: 10.1007/s00277-017-2980-3. Epub 2017 Mar 23.

12.

Determination of mild, moderate, and severe pain interference in patients with cancer.

Shi Q, Mendoza TR, Dueck AC, Ma H, Zhang J, Qian Y, Bhowmik D, Cleeland CS.

Pain. 2017 Jun;158(6):1108-1112. doi: 10.1097/j.pain.0000000000000890.

PMID:
28267060
13.

Sleep quality and its association with fatigue, symptom burden, and mood in patients with advanced cancer in a clinic for early-phase oncology clinical trials.

George GC, Iwuanyanwu EC, Anderson KO, Yusuf A, Zinner RG, Piha-Paul SA, Tsimberidou AM, Naing A, Fu S, Janku F, Subbiah V, Cleeland CS, Mendoza TR, Hong DS.

Cancer. 2016 Nov 15;122(21):3401-3409. doi: 10.1002/cncr.30182. Epub 2016 Jul 14.

14.

Validity and Reliability of the Indonesian Version of the Brief Fatigue Inventory in Cancer Patients.

Paramita N, Nusdwinuringtyas N, Nuhonni SA, Atmakusuma TD, Ismail RI, Mendoza TR, Cleeland CS.

J Pain Symptom Manage. 2016 Nov;52(5):744-751. doi: 10.1016/j.jpainsymman.2016.04.011. Epub 2016 Sep 19.

PMID:
27660081
15.

Using a symptom-specific instrument to measure patient-reported daily functioning in patients with cancer.

Shi Q, Mendoza TR, Wang XS, Cleeland CS.

Eur J Cancer. 2016 Nov;67:83-90. doi: 10.1016/j.ejca.2016.07.027. Epub 2016 Sep 9.

PMID:
27620946
16.

The utility of patient-reported outcome measures among patients with myalgic encephalomyelitis/chronic fatigue syndrome.

Murdock KW, Wang XS, Shi Q, Cleeland CS, Fagundes CP, Vernon SD.

Qual Life Res. 2017 Apr;26(4):913-921. doi: 10.1007/s11136-016-1406-3. Epub 2016 Sep 6.

17.

Patient-Reported Symptom Interference as a Measure of Postsurgery Functional Recovery in Lung Cancer.

Shi Q, Wang XS, Vaporciyan AA, Rice DC, Popat KU, Cleeland CS.

J Pain Symptom Manage. 2016 Dec;52(6):822-831. doi: 10.1016/j.jpainsymman.2016.07.005. Epub 2016 Aug 10.

18.

Validity and reliability of a Turkish Brief Pain Inventory Short Form when used to evaluate musculoskeletal pain.

Celik EC, Yalcinkaya EY, Atamaz F, Karatas M, Ones K, Sezer T, Eren I, Paker N, Gning I, Mendoza T, Cleeland CS.

J Back Musculoskelet Rehabil. 2017;30(2):229-233. doi: 10.3233/BMR-160738.

PMID:
27472857
19.

Intensity Modulated Proton Therapy Versus Intensity Modulated Photon Radiation Therapy for Oropharyngeal Cancer: First Comparative Results of Patient-Reported Outcomes.

Sio TT, Lin HK, Shi Q, Gunn GB, Cleeland CS, Lee JJ, Hernandez M, Blanchard P, Thaker NG, Phan J, Rosenthal DI, Garden AS, Morrison WH, Fuller CD, Mendoza TR, Mohan R, Wang XS, Frank SJ.

Int J Radiat Oncol Biol Phys. 2016 Jul 15;95(4):1107-14. doi: 10.1016/j.ijrobp.2016.02.044. Epub 2016 Feb 18.

20.

Enhancing quality of life as a goal for anticancer therapeutics.

Pettit SD, Lipshultz SE, Cleeland CS, Roberts S, Davis M, Berridge BR, Kirch RA.

Sci Transl Med. 2016 Jun 22;8(344):344ed9. doi: 10.1126/scitranslmed.aag0382.

PMID:
27334258
21.

Linguistic Validation of the Turkish Version of the M.D. Anderson Symptom Inventory - Head and Neck Cancer Module.

Gunn GB, Atalar B, Mendoza TR, Cleeland CS, Selek U, Özyar E, Rosenthal DI.

Balkan Med J. 2016 May;33(3):339-43. doi: 10.5152/balkanmedj.2015.150148. Epub 2016 May 1.

22.

Prospective Study of Patient-Reported Symptom Burden in Patients With Non-Small-Cell Lung Cancer Undergoing Proton or Photon Chemoradiation Therapy.

Wang XS, Shi Q, Williams LA, Komaki R, Gomez DR, Lin SH, Chang JY, O'Reilly MS, Bokhari RH, Cox JD, Mohan R, Cleeland CS, Liao Z.

J Pain Symptom Manage. 2016 May;51(5):832-8. doi: 10.1016/j.jpainsymman.2015.12.316. Epub 2016 Feb 16.

23.

Prechemotherapy Touch Sensation Deficits Predict Oxaliplatin-Induced Neuropathy in Patients with Colorectal Cancer.

Wang XS, Shi Q, Dougherty PM, Eng C, Mendoza TR, Williams LA, Fogelman DR, Cleeland CS.

Oncology. 2016;90(3):127-35. doi: 10.1159/000443377. Epub 2016 Feb 17.

24.

[Properties of the Measures to Assess Oxaliplatin-induced Peripheral Neuropathy: A Literature Review].

Chu SH, Lee YJ, Lee YJ, Cleeland CS.

J Korean Acad Nurs. 2015 Dec;45(6):783-801. doi: 10.4040/jkan.2015.45.6.783. Review. Korean.

PMID:
26805492
25.

The Added Value of Analyzing Pooled Health-Related Quality of Life Data: A Review of the EORTC PROBE Initiative.

Zikos E, Coens C, Quinten C, Ediebah DE, Martinelli F, Ghislain I, King MT, Gotay C, Ringash J, Velikova G, Reeve BB, Greimel E, Cleeland CS, Flechtner H, Taphoorn MJ, Weis J, Schmucker-von Koch J, Sprangers MA, Bottomley A; EORTC PROBE.

J Natl Cancer Inst. 2015 Dec 28;108(5). pii: djv391. doi: 10.1093/jnci/djv391. Print 2016 May. Review.

26.

Working after a metastatic cancer diagnosis: Factors affecting employment in the metastatic setting from ECOG-ACRIN's Symptom Outcomes and Practice Patterns study.

Tevaarwerk AJ, Lee JW, Terhaar A, Sesto ME, Smith ML, Cleeland CS, Fisch MJ.

Cancer. 2016 Feb 1;122(3):438-46. doi: 10.1002/cncr.29656. Epub 2015 Dec 21.

27.

Patient-Reported Outcomes Accurately Measure the Value of an Enhanced Recovery Program in Liver Surgery.

Day RW, Cleeland CS, Wang XS, Fielder S, Calhoun J, Conrad C, Vauthey JN, Gottumukkala V, Aloia TA.

J Am Coll Surg. 2015 Dec;221(6):1023-30.e1-2. doi: 10.1016/j.jamcollsurg.2015.09.011. Epub 2015 Oct 21.

PMID:
26611799
28.

Favorable patient reported outcomes following IMRT for early carcinomas of the tonsillar fossa: Results from a symptom assessment study.

Gunn GB, Hansen CC, Garden AS, Fuller CD, Mohamed AS, Morrison WH, Frank SJ, Beadle BM, Phan J, Chronowski GM, Sturgis EM, Lewis CM, Lu C, Hutcheson KA, Mendoza TR, Cleeland CS, Rosenthal DI.

Radiother Oncol. 2015 Oct;117(1):132-8. doi: 10.1016/j.radonc.2015.09.007. Epub 2015 Sep 21.

29.

Validity and Reliability of the US National Cancer Institute's Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE).

Dueck AC, Mendoza TR, Mitchell SA, Reeve BB, Castro KM, Rogak LJ, Atkinson TM, Bennett AV, Denicoff AM, O'Mara AM, Li Y, Clauser SB, Bryant DM, Bearden JD 3rd, Gillis TA, Harness JK, Siegel RD, Paul DB, Cleeland CS, Schrag D, Sloan JA, Abernethy AP, Bruner DW, Minasian LM, Basch E; National Cancer Institute PRO-CTCAE Study Group.

JAMA Oncol. 2015 Nov;1(8):1051-9. doi: 10.1001/jamaoncol.2015.2639. Erratum in: JAMA Oncol. 2016 Jan;2(1):146.

30.

Higher Stem Cell Dose Infusion after Intensive Chemotherapy Does Not Improve Symptom Burden in Older Patients with Multiple Myeloma and Amyloidosis.

Shah N, Shi Q, Williams LA, Mendoza TR, Wang XS, Reuben JM, Dougherty PM, Bashir Q, Qazilbash MH, Champlin RE, Cleeland CS, Giralt SA.

Biol Blood Marrow Transplant. 2016 Feb;22(2):226-231. doi: 10.1016/j.bbmt.2015.07.036. Epub 2015 Aug 5.

31.

Measuring Therapy-Induced Peripheral Neuropathy: Preliminary Development and Validation of the Treatment-Induced Neuropathy Assessment Scale.

Mendoza TR, Wang XS, Williams LA, Shi Q, Vichaya EG, Dougherty PM, Thomas SK, Yucel E, Bastida CC, Woodruff JF, Cleeland CS.

J Pain. 2015 Oct;16(10):1032-43. doi: 10.1016/j.jpain.2015.07.002. Epub 2015 Jul 22.

32.

Symptom recovery after thoracic surgery: Measuring patient-reported outcomes with the MD Anderson Symptom Inventory.

Fagundes CP, Shi Q, Vaporciyan AA, Rice DC, Popat KU, Cleeland CS, Wang XS.

J Thorac Cardiovasc Surg. 2015 Sep;150(3):613-9.e2. doi: 10.1016/j.jtcvs.2015.05.057. Epub 2015 May 28.

33.

Symptom management of gynecologic cancers: refocusing on the forest.

Cleeland CS, Rose SL.

Gynecol Oncol. 2015 Mar;136(3):413-4. doi: 10.1016/j.ygyno.2015.01.555. No abstract available.

PMID:
25752571
34.

Automated pain intervention for underserved minority women with breast cancer.

Anderson KO, Palos GR, Mendoza TR, Cleeland CS, Liao KP, Fisch MJ, Garcia-Gonzalez A, Rieber AG, Nazario LA, Valero V, Hahn KM, Person CL, Payne R.

Cancer. 2015 Jun 1;121(11):1882-90. doi: 10.1002/cncr.29204. Epub 2015 Feb 24.

35.

Pain outcomes in patients with bone metastases from advanced cancer: assessment and management with bone-targeting agents.

Patrick DL, Cleeland CS, von Moos R, Fallowfield L, Wei R, Öhrling K, Qian Y.

Support Care Cancer. 2015 Apr;23(4):1157-68. doi: 10.1007/s00520-014-2525-4. Epub 2014 Dec 23. Review.

PMID:
25533578
36.

Racial/ethnic disparities in inflammatory gene single-nucleotide polymorphisms as predictors of a high risk for symptom burden in patients with multiple myeloma 1 year after diagnosis.

Shi Q, Wang XS, Li G, Shah ND, Orlowski RZ, Williams LA, Mendoza TR, Cleeland CS.

Cancer. 2015 Apr 1;121(7):1138-46. doi: 10.1002/cncr.29154. Epub 2014 Dec 2.

37.

The symptom burden of treatment-naive patients with head and neck cancer.

Hanna EY, Mendoza TR, Rosenthal DI, Gunn GB, Sehra P, Yucel E, Cleeland CS.

Cancer. 2015 Mar 1;121(5):766-73. doi: 10.1002/cncr.29097. Epub 2014 Nov 4.

38.

Development of the National Cancer Institute's patient-reported outcomes version of the common terminology criteria for adverse events (PRO-CTCAE).

Basch E, Reeve BB, Mitchell SA, Clauser SB, Minasian LM, Dueck AC, Mendoza TR, Hay J, Atkinson TM, Abernethy AP, Bruner DW, Cleeland CS, Sloan JA, Chilukuri R, Baumgartner P, Denicoff A, St Germain D, O'Mara AM, Chen A, Kelaghan J, Bennett AV, Sit L, Rogak L, Barz A, Paul DB, Schrag D.

J Natl Cancer Inst. 2014 Sep 29;106(9). pii: dju244. doi: 10.1093/jnci/dju244. Print 2014 Sep.

39.

Current use of drugs affecting the central nervous system for chemotherapy-induced peripheral neuropathy in cancer patients: a systematic review.

Chu SH, Lee YJ, Lee ES, Geng Y, Wang XS, Cleeland CS.

Support Care Cancer. 2015 Feb;23(2):513-24. doi: 10.1007/s00520-014-2408-8. Epub 2014 Sep 26. Review.

PMID:
25256375
40.

Longitudinal analysis of patient-reported symptoms post-autologous stem cell transplant and their relationship to inflammation in patients with multiple myeloma.

Wang XS, Shi Q, Williams LA, Shah ND, Mendoza TR, Cohen EN, Reuben JM, Cleeland CS, Orlowski RZ.

Leuk Lymphoma. 2015 May;56(5):1335-41. doi: 10.3109/10428194.2014.956313. Epub 2014 Nov 20.

41.

Impact of symptom burden on work-related abilities in patients with locally recurrent or metastatic breast cancer: Results from a substudy of the VIRGO observational cohort study.

Cleeland CS, Mayer M, Dreyer NA, Yim YM, Yu E, Su Z, Mun Y, Sloan JA, Kaufman PA.

Breast. 2014 Dec;23(6):763-9. doi: 10.1016/j.breast.2014.08.004. Epub 2014 Sep 3.

PMID:
25193423
42.

A quantitative sensory analysis of peripheral neuropathy in colorectal cancer and its exacerbation by oxaliplatin chemotherapy.

de Carvalho Barbosa M, Kosturakis AK, Eng C, Wendelschafer-Crabb G, Kennedy WR, Simone DA, Wang XS, Cleeland CS, Dougherty PM.

Cancer Res. 2014 Nov 1;74(21):5955-62. doi: 10.1158/0008-5472.CAN-14-2060. Epub 2014 Sep 2.

43.
44.

Subclinical peripheral neuropathy in patients with multiple myeloma before chemotherapy is correlated with decreased fingertip innervation density.

Kosturakis AK, He Z, Li Y, Boyette-Davis JA, Shah N, Thomas SK, Zhang H, Vichaya EG, Wang XS, Wendelschafer-Crabb G, Kennedy WR, Simone DA, Cleeland CS, Dougherty PM.

J Clin Oncol. 2014 Oct 1;32(28):3156-62. doi: 10.1200/JCO.2013.54.5418. Epub 2014 Aug 25.

45.

Nomogram for predicting symptom severity during radiation therapy for head and neck cancer.

Sheu T, Fuller CD, Mendoza TR, Garden AS, Morrison WH, Beadle BM, Phan J, Frank SJ, Hanna EY, Lu C, Cleeland CS, Rosenthal DI, Gunn GB.

Otolaryngol Head Neck Surg. 2014 Oct;151(4):619-26. doi: 10.1177/0194599814545746. Epub 2014 Aug 7.

46.

Symptom burden in hematologic malignancies.

Cleeland CS, Williams LA.

Blood. 2014 Jun 12;123(24):3686-7. doi: 10.1182/blood-2014-03-558981. No abstract available.

47.

Measuring symptoms as a critical component of drug development and evaluation in hematological diseases.

Williams LA, Yucel E, Cortes JE, Cleeland CS.

Clin Investig (Lond). 2013 Dec 1;3(12):1127-1138.

48.

Symptom burden of cancer patients: validation of the German M. D. Anderson Symptom Inventory: a cross-sectional multicenter study.

Schmidt H, Cleeland CS, Bauer A, Landenberger M, Jahn P.

J Pain Symptom Manage. 2015 Jan;49(1):117-25. doi: 10.1016/j.jpainsymman.2014.04.007. Epub 2014 May 23.

PMID:
24858739
49.

Effects of denosumab on pain and analgesic use in giant cell tumor of bone: interim results from a phase II study.

Martin-Broto J, Cleeland CS, Glare PA, Engellau J, Skubitz KM, Blum RH, Ganjoo KN, Staddon A, Dominkus M, Feng A, Qian Y, Braun A, Jacobs I, Chung K, Atchison C.

Acta Oncol. 2014 Sep;53(9):1173-9. doi: 10.3109/0284186X.2014.910313. Epub 2014 May 19.

PMID:
24834795
50.

Patterns of symptom burden during radiotherapy or concurrent chemoradiotherapy for head and neck cancer: a prospective analysis using the University of Texas MD Anderson Cancer Center Symptom Inventory-Head and Neck Module.

Rosenthal DI, Mendoza TR, Fuller CD, Hutcheson KA, Wang XS, Hanna EY, Lu C, Garden AS, Morrison WH, Cleeland CS, Gunn GB.

Cancer. 2014 Jul 1;120(13):1975-84. doi: 10.1002/cncr.28672. Epub 2014 Apr 7.

Supplemental Content

Loading ...
Support Center